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Left ventricular assistdevice (LVAD)use hasincreased as abridge to heart transplantaswell as destinationtherapy inpatients with
severe heart failure. Presence of LVAD is not a contraindication to noncardiac surgery but does present special challenges to the
surgical, anesthesia,and cardiac teams. We present the case of a 40-year-old womanwith idiopathic cardiomyopathy necessitating
LVAD who underwent left partial nephrectomy for a renal mass. She had undergone three nondiagnostic percutaneous image-
guided biopsies. Left partial nephrectomy was performed. Perioperative care was without incident due to careful oversight
by a multidisciplinary team. Pathology revealed high-grade clear cell renal cell carcinoma (RCC) with negative margins.
Polytetraﬂuoroethylene (PTFE) bolsters were misidentiﬁed six months postoperatively on computed tomography (CT) at an
outside institution as a retained laparotomysponge. This is, to our knowledge, the ﬁrst report of a partial nephrectomy performed
in a patient with LVAD.
1.Introduction
Left ventricular assist device (LVAD) use has increased and
become more successful and durable. It is the standard-of-
care bridge to heart transplant in patients with severe car-
diomyopathy [1]. It is also being used as destination therapy
insomepatients.NoncardiacsurgeryiscomplicatedinLVAD
due to the position of the device, need for anticoagulation,
and tenuous hemodynamics of these patients. Nevertheless,
successful noncardiac surgery in LVAD patients occurs
when careful coordination between anesthetic, cardiac, and
surgical teams takes place [2–4].
2.Case
A 40-year-old African-American female with a history of
idiopathic familial cardiomyopathy was being evaluated for
heart transplantation. Eleven months earlier, she had a CT
abdomen performed as part of a cardiac transplant workup
which revealed a 1.5cmenhancing left upperpole renal mass
(Figure 1). Given her age, it was possible that this lesion was
a benign tumor such as angiomyolipoma or oncocytoma.
Therefore, she underwent a CT-guided biopsy of this mass
to reconcile the issue prior to heart transplant. This biopsy
proved inconclusive due to insuﬃcient tissue, and a second
attemptwasmadeunderconscioussedationsixmonthsprior
to LVAD placement. This attempt had to be aborted when
she developed severe chest pain and dyspnea preventing
adequate sampling. As her ejection fraction worsened, she
became progressively dyspneic at rest and received a Heart-
mate II LVAD (Thoratec Corp., Pleasanton, CA). After much
discussion of options, she underwent a CT-guided biopsy
under general anesthesia which revealed oncocytic-type cells
with ﬁne needle aspiration but again was nondiagnostic. By
the time the patient developed severe decompensated heart
failure necessitating LVAD placement, the mass had grown
to 2.7cm (Figure 1).
The patient had a past medical history of a nonischemic
cardiomyopathy and resultant heart failure manifested by
orthopnea,dyspneaonexertion,paroxysmalnocturnaldysp-
nea, palpitations, and angina. Transthoracic echocardiogram
revealed a dilated and hypertrophic left ventricle with a
left ventricular ejection fraction of 10–15% with no signif-
icant valvular pathology. Cardiac catheterization revealed2 Case Reports in Urology
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Figure 1: Serialcontrasted CT scan ofthe abdomen demonstrating
interval growth of enhancing left renal mass (12, 8, 4 months prior
to partial nephrectomy).
the absence of coronary artery disease. She had undergone
an implantable cardiac deﬁbrillator due to her diminished
ejection fraction, but the device had never discharged.
Preoperatively, physical examination revealed a well-
nourished, well-developed woman (70kg, BMI 23.4) who
was an active participant in decision making. She carried
the LVAD in a satchel and had the expected vital signs for
a patient with an LVAD. She had a well-healed scar over
her sternum and upper abdomen. Trace pedal edema was
present. Laboratory examination revealed hemoglobin of
9.2g/dL, serum creatinine 0.9mg/dL (estimated glomerular
ﬁltration rate 92mL/min), international normalized ratio
(INR) 2.6, and negative urine culture.
The decision was made to perform partial nephrectomy
due to the imaging characteristics and growth rate of the
mass and the imperative to clear her of a potential renal cell
carcinoma in the setting of cardiac transplant listing. Given
the need for future immunosuppression, the cardiologist,
urologist, and cardiac surgeon felt that maximization of
nephrons outweighed the risk of transient bleeding that may
have been avoided by performing a radical nephrectomy.
Percutaneous ablative approaches were not considered due
to tumor location. The cardiology team assisted in medically
maximizing the patient preoperatively. The patient was
preadmitted to the urology service to facilitate the coordi-
nation of care. She was given a gentle bowel preparation
of magnesium citrate along with one day of clear liquids.
She was maintained oﬀ warfarin for 3 days preoperatively
with therapeutic-dose enoxaparin which was discontinued
the morning of surgery. Her INR on admission was 1.5.
Anesthesiology was consulted, and the case was coordinated
toensurethatacardiacanesthesiologistadministered general
anesthesia. Additionally, the cardiac surgeon was available in
the operating room the morning of the surgery.
General anesthesia was initiated, and an arterial line
was placed with the cardiac surgeon standing by. Extensive
padding was utilized with respect to the LVAD as the patient
was positioned in the left modiﬁed ﬂank position. To avoid
excessive pressure points, the kidney rest was not utilized.
From a retroperitoneal approach just oﬀ the eleventhrib, the
kidney was freed and the hilum dissected. At no point did
the LVAD present any diﬃculties. The lesion was not readily
identiﬁed on gross inspection. Intraoperative ultrasound
revealed the mass in the superior pole abutting the collecting
system. After injection of 6mg of mannitol, the renal artery
was clamped and then iced. After ﬁfteen minutes of cooling,
the capsule was scored with argon plasma coagulation and
resection of the mass was performed with the blunt edge
of a knife handle. Inferior and deep margins were sent for
frozen examination and found to be negative for tumor.
The collecting system was closed with 4–0 poliglecaprone
suture. Argon plasma coagulation was performed to the
resection bed. A Surgicel (Ethicon, Inc., Somerville, NJ)
bolster and Avitene powder (Alcon, Inc., Humacao, Puerto
Rico) were placed in the defect. The defect was closed with a
0-chromic suture on a liver needle bolstered with a strip of
polytetraﬂuoroethylene (PTFE) pledget both anteriorly and
posteriorly. Unclamping was performed for a total clamp
time of 59 minutes, and the kidney was observed for 15
minutes. FloSeal (Baxter International Inc., Deerﬁeld, IL)
coagulation matrix was applied to the defect and hilum
and argon plasma coagulation was performed on some
oozing portions of Gerota’s fascia. Gerota’s fascia was then
used to cover the kidney again. A 1.5cm defect in the
pleura was closed with 2–0 polyglactin, and the air was
evacuated with a red rubber catheter. A Jackson-Pratt drain
was left in the retroperitoneum to bulb suction, and the
woundwasclosed.Thepatientwasextubatedandtransferred
to the cardiac care unit for postoperative care. The patient
received at total of 3 units of packed red blood cells and
one unit of fresh frozen plasma. Estimated blood loss was
500mL.Case Reports in Urology 3
Postoperative chest radiograph revealed no pneumoth-
orax. Warfarin and enoxaparin were resumed on postopera-
tivedaystwoandfour, respectively.Furosemidewasrestarted
on postoperative day number one. The patient had her diet
quickly advanced, and pain was controlled on oral narcotics.
She was up and ambulatory, tolerating a low-sodium diet
and had all of her heart failure medications restarted.
Her Jackson-Pratt drain was removed on postoperative day
number 4, and she went home on postoperative day number
6. Final pathology revealed clear cell RCC 2.6 × 2.0 ×
1.5cmwithnegativemargins, Fuhrmangrade3(highgrade).
The serum creatinine upon discharge was 0.8mg/dL (eGFR
103mL/min).
Her managed care consortium mandated postdischarge
urologic care be performed at an outside institution. Her
postoperative check was unremarkable, but at her 6 month
followup she was experiencing worsening left ﬂank pain. CT
scan of the abdomen revealed a radiodense material over
the superolateral aspect of the left kidney (Figure 2). The
ﬁnal impression stated that there was a retained laparotomy
sponge, and the patient was informed that she would
require further surgery. This distressed the patient, and
she immediately wanted to return to the original surgeon,
but the managed care consortium required prior approval
which caused a 2-month delay in return to our clinic for
evaluation.Upon reevaluation, plain abdominal radiographs
were obtained in both the posterior-anterior and oblique
orientations. This did not reveal ribbon-like radiopaque
material which would be consistent with a retained
laparotomy sponge (Figure 3). Reassurance was provided.
3.Discussion
Noncardiac surgery can be safely and successfully performed
in the setting of careful coordination between the surgical
team and cardiology, cardiac anesthesiology, and cardiotho-
racic surgery teams. While nephrectomy [4] and pyelolitho-
tomy [3] have been described in patients with LVAD, this
is the ﬁrst report to our knowledge of partial nephrectomy
in such a patient. Management of renal cell carcinoma with
nephron-sparing therapies has been increasing and is the
standard of care in renal masses less than 4cm. Nephron
sparing is particularly crucial in patients with comorbidities
which pose a long term threat to renal function such as
heart disease, obesity, and diabetes mellitus. This patient
had another future threat to her renal function in the form
of calcineurin-inhibitor nephrotoxicity associated with heart
transplantation.
Communication was central to the success of this opera-
tive course. Preoperative evaluation by cardiology team and
real-time consultations between urologist and anesthesiol-
ogist is critical to the success. The infrequent nature of
concurrent malignancy in a heart transplant candidate with
an LVAD means that there will never be a “process” of
care pathway for these patients. Inclusion of this cardiac
anesthesiologist was invaluable in terms of their experience
with these patients. An arterial line was placed to monitor
the pressure as noninvasive blood pressure monitoring is not
Figure 2: Postoperative CT abdomen demonstrating PTFE bolster
on left kidney.
Figure 3: Conﬁrmation of no retained sponge with series of ab-
dominal plain ﬁlms.
reliable in patients with continuous ﬂow LVAD. The blood
bank was prepared for the case and the appropriate blood
products were available for transfusion. Cardiothoracic
surgery was aware and in the operative suite in the event
of any complication with the device or questions regarding
the surgical anatomy. Postoperative care was performed by
the cardiac intensive care unit with the urology team as
consultants. It is the practice at our institution for patients
with LVAD to be admitted to the cardiology service because
of the complexity of these patients.
Careful surgical technique along with hemostatic agents
and bolstered sutures enable partial nephrectomy to be per-
formed without signiﬁcant postoperative bleeding in most
patients. Partial nephrectomy is high-risk surgery in patients
requiring chronic anticoagulation due to both bleeding [5]
and thrombotic [6] complications. In fact, at our institution,
initiation of anticoagulation (even prophylactic dose) or
antiplatelet agents is avoided after partial nephrectomy.
Due to the fact that the patient had a HeartMate II device4 Case Reports in Urology
rather than pulsatile ﬂow device, there was no necessity of
immediate postoperative anticoagulation [7]. Nevertheless,
reinstitutionofwarfarin and enoxaparin assoon as surgically
safe was recommended.
An interesting aspect of this case was the failure to diag-
noserenalcellcarcinomapreoperatively.Itisnotourpractice
to biopsy enhancing renal masses priorto performing partial
nephrectomy. However, in the setting of young age, chronic
anticoagulation, and severe heart failure, tissue diagnosis
was sought. On three separate occasions, percutaneous CT-
guided biopsy of the mass failed to yield a diagnosis. We
often perform renal biopsy in concert with ablative therapies
but rarely biopsy renal masses prior to surgery. This case
illustrates one of the common pitfalls with percutaneous
renalbiopsywhichisinabilitytoobtainanaccuratediagnosis
[8].
The reason that partial nephrectomy was performed in
this high-risk patient without tissue diagnosis is that she was
on the heart transplant list. Search for malignancy is per-
formed prior to heart transplant. Patients will be depriori-
tizeduntiltheseissuesareresolved.Oneofthemostcommon
causes of late death in cardiac transplant is immunosuppres-
sion-driven malignancy. Retrospective studies and animal
models have demonstrated that immunosuppression is not
only a known risk of de novo malignancies but also fuels
recurrence, progression, and metastasis of known or even
treated lesions [9–13].
The renal capsule and parenchymal defect was reapprox-
imated in this case with hemostatic suture utilizing PTFE
pledgets to redistribute the forces of the suture and prevent
tearing of the renal capsule and kidney parenchyma. Such a
large strip would not usually be used, but this patient had
moderate blood loss due to both the position of the tumor
and her chronic anticoagulation. This increased volume of
PTFE was needed to secure hemostasis. PTFE is a material
with broad applications in cardiac, vascular, and general
surgery. It is radiodense on CT but not radiopaque on plain
ﬁlm. Itsuse in partial nephrectomy has been described in the
literature [14, 15] as well as its radiologic characteristics on
CT[16].However,itsapplicationinpartial nephrectomyand
imaging characteristics are not well known by the medical
community. We have observed several outside radiologists
who misidentify PTFE pledgets as retained laparotomy
sponge. This causes a great deal of distress and anxiety to the
patient and yields unnecessary testing and cost as evidenced
by this case.
We present the case of a partial nephrectomy performed
in a 40-year-old woman with idiopathic cardiomyopathy.
Noncardiac surgeries, even those with a high risk of bleeding
complications, may be performed in the setting of LVAD as a
multidisciplinary eﬀort at a tertiary care center. Principles of
surgery in such patients include the following:
(i) communicationbetween cardiology,cardiacanesthe-
sia, cardiothoracic surgery, and the primary surgical
team;
(ii) thoughtful perioperative anticoagulation with less
stringent requirement in continuous ﬂow devices;
(iii) arterial line for hemodynamic monitoring particu-
larly in continuous ﬂow devices;
(iv) careful positioning and avoidance of the device and
drivelines;
(v) generous use of hemostatic techniques and agents.
This case illustrates the imperative for diagnosis and
treatment ofsuspiciousrenal mass inpotential transplant re-
cipients since immunosuppression drives tumorigenesis and
tumor growth in many malignancies including RCC. This is
a case of unsatisfying results from percutaneous biopsy of a
renal mass. Finally, highlighted is the lack of awareness of
PTFE use in partial nephrectomy and its radiographic char-
acteristics.
References
[1] F. D. Pagani,L. W. Miller, S.D. Russell et al., “Extended mech-
anical circulatory support with a continuous-ﬂow rotary left
ventricular assist device,” Journal of the American College of
Cardiology, vol. 54, no. 4, pp. 312–321, 2009.
[2] B.Wei,H.Takayama,andM.D. Bacchetta,“Pulmonarylobec-
tomy in a patient with a left ventricular assist device,” Annals
of Thoracic Surgery, vol. 87, no. 6, pp. 1934–1936, 2009.
[3] A .G arat t i,G .Bru sc hi,T .C olomb oe tal. ,“ N onc ar d iacsu r gic al
procedures in patient supported with long-term implantable
left ventricular assistdevice,” American Journal of Surgery,v o l .
197, no. 6, pp. 710–714, 2009.
[4] D. J. Goldstein, S. L. Mullis, E. S. Delphin et al., “Noncardiac
surgery in long-termimplantableleft ventricular assist-device
recipients,” Annals of Surgery, vol. 222, no. 2, pp. 203–207,
1995.
[5] I. M. Varkarakis, S. Rais-Bahrami, M. E. Allaf et al., “Laparo-
scopic renal-adrenal surgery in patients on oral anticoagulant
therapy,” Journal of Urology, vol. 174, no. 3, pp. 1020–1023,
2005.
[6] J .C.K efer ,M.M.Desai,A.F ergan y ,A.C.N ovick,andI.S.Gill,
“Outcomes of partial nephrectomy in patients onchronic oral
anticoagulant therapy,” Journal of Urology, vol. 180, no. 6, pp.
2370–2374, 2008.
[7] R. John, F. Kamdar, K. Liao et al., “Low thromboembolic risk
for patients with the Heartmate II left ventricular assist de-
vice,” Journal of Thoracic and Cardiovascular Surgery, vol. 136,
no. 5, pp. 1318–1323, 2008.
[ 8 ]R .B .S h a h ,N .B a k s h i ,K .S .H a f e z ,D .P .W o o dJ r . ,a n dL .
P. Kunju, “Image-guided biopsy in the evaluation of renal
mass lesions in contemporary urological practice: indications,
adequacy, clinical impact, and limitations of the pathological
diagnosis,” Human Pathology, vol. 36, no. 12, pp. 1309–1315,
2005.
[9] I.Penn,“Evaluationoftransplantcandidates withpre-existing
malignancies,” Annals of Transplantation, vol. 2, no. 4, pp. 14–
17, 1997.
[10] I. Penn, “Occurrence of cancers in immunosuppressed organ
transplantrecipients,” Clinical Transplants, pp. 147–158,1998.
[11] M. Hojo, T. Morimoto, M. Maluccio et al., “Cyclosporine in-
duces cancer progression by a cell-autonomous mechanism,”
Nature, vol. 397, no. 6719, pp. 530–534, 1999.
[12] M. Kaartinen, M. Eray, E. Lehtonen, A. Matoso-Ferreira, and
J. Tienari, “Implanted solid human tumours grow under the
renal capsule of cyclosporin- immunosuppressed rats,” Scan-
dinavian Journal of Immunology, vol. 39, no. 6, pp. 618–624,
1994.Case Reports in Urology 5
[13] M. Pollard, “Enhancement of metastasis of prostate adenocar-
cinoma cells by immune-suppressive cyclosporine A,” Cancer
Letters, vol. 111, no. 1-2, pp. 221–224, 1997.
[14] H. Zincke and H. C. Ruckle, “Use of exogenous material to
bolster closure of the parenchymal defect following partial
nephrectomy,” Urology, vol. 46, no. 1, pp. 96–98, 1995.
[15] D. S. Park and W. K. Jang, “Secure reconstruction technique
after partial nephrectomy irrespective of tumor size and
location,” International Brazilian Journal of Urology,v o l .3 5 ,
no. 4, pp. 416–423, 2009.
[16] D. A. Aguirre, A. C. Santosa, G. Casola, and C. B. Sirlin,
“Abdominal wall hernias: imaging features, complications,
and diagnostic pitfalls at multi-detector row CT,” Radiograph-
ics, vol. 25, no. 6, pp. 1501–1520, 2005.